STOCK TITAN
  1. Home
  2. News
  3. HRGN

HARVARD APPRATS REG TCH - $HRGN STOCK NEWS

Welcome to our dedicated page for HARVARD APPRATS REG TCH news (Ticker: $HRGN), a resource for investors and traders seeking the latest updates and insights on HARVARD APPRATS REG TCH stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HARVARD APPRATS REG TCH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HARVARD APPRATS REG TCH's position in the market.

News
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Harvard Apparatus Regenerative Technology, Inc. announced several collaborations and milestones, including a research partnership with the McGowan Institute for Regenerative Medicine, a clinical trial site activation, and an orphan disease application approval. The company also reported financial results for the fourth quarter and full year 2023, showing a net loss increase year-over-year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
Rhea-AI Summary
Harvard Apparatus Regenerative Technology, Inc. (HRGN) has officially executed a sponsored research agreement with the University of Pittsburgh and UPMC to develop regenerative therapies for organ and tissue failure. The program will focus on repairing the colon following colectomy, a surgical procedure for conditions like cancer and inflammatory bowel disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
News
Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
Rhea-AI Summary
Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) has officially executed a Sponsored Research Agreement (SRA) with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine. The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to restore fertility by repairing uterine tissue in a mouse model of uterine damage. IUAs have a debilitating impact on the health and quality of life in women of childbearing age while the economic burden is substantial. This initiative aims to treat infertility in women that require repair or regeneration of their uterine tissue, providing a significant advancement in women’s health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
News
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Harvard Apparatus Regenerative Technology, Inc. (HRGN) Announces Financial Results and Operating Highlights, Including Expansion of Clinical Trial Sites and European Medicines Agency Approval
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results
Rhea-AI Summary
HRGN: Harvard Apparatus Regenerative Technology, Inc. to Release Q3 2023 Financial Results on November 13, 2023. The clinical-stage biotechnology company will discuss financial results and business updates during a conference call and webcast at 9:00 AM ET. Q&A session included.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Activated University of Michigan as The Second Site for Clinical Trial in Severe Esophageal Disease
Rhea-AI Summary
Harvard Apparatus Regenerative Technology activates second site for clinical trial on severe esophageal disease, accelerating development timelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
clinical trial
News
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q2 2023 Results
Rhea-AI Summary
Harvard Apparatus Regenerative Technology, Inc. (HRGN) to release Q2 2023 financial results on August 14, 2023, and host a conference call and webcast to discuss financial results and business updates for the second quarter. The company is a clinical-stage biotechnology company developing technology to regenerate organs inside the body to treat severe diseases, including cancer, trauma, and birth defects in the esophagus and other organs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
earnings
Stock HRGN logo
HARVARD APPRATS REG TCH

OTC:HRGN

HRGN Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

HRGN Stock Data

37.10M
6.22M
49.5%
6.25%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
Holliston

About HRGN

biostage, inc. (otcqb: bstg) is a pioneering biotechnology company developing bioengineered organ implants to address unmet needs in the treatment of life-threatening cancer, traumas and congenital abnormalities of the esophagus, bronchus and trachea. the company’s cellframe™ technology platform is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. combining a synthetic scaffold with tissue engineering and cell biology, biostage’s cellframe™ platform is used to create organ specific cellspan™ implants. the cellspan™ implant is delivered directly to the site where tissue regeneration is needed, and has been designed to promote in situ tissue regeneration by providing both stem cell-derived biological signals, and three-dimensional guidance and support for cell growth differentiation. recent large animal data delivered promising results as cellframe™-based cellspan™ implants applied to the esophagus achieved regener